HRPK20040255B3 - Processes for preparing calcium salt forms of statins - Google Patents
Processes for preparing calcium salt forms of statinsInfo
- Publication number
- HRPK20040255B3 HRPK20040255B3 HR20040255A HRP20040255A HRPK20040255B3 HR PK20040255 B3 HRPK20040255 B3 HR PK20040255B3 HR 20040255 A HR20040255 A HR 20040255A HR P20040255 A HRP20040255 A HR P20040255A HR PK20040255 B3 HRPK20040255 B3 HR PK20040255B3
- Authority
- HR
- Croatia
- Prior art keywords
- calcium salt
- statins
- processes
- salt forms
- preparing calcium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31281201P | 2001-08-16 | 2001-08-16 | |
US10/037,412 US6528661B2 (en) | 2000-11-16 | 2001-10-24 | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
PCT/US2002/026012 WO2003016317A1 (fr) | 2001-08-16 | 2002-08-16 | Procedes permettant de preparer des formes salines calciques de statines |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20040255A2 HRP20040255A2 (en) | 2004-08-31 |
HRPK20040255B3 true HRPK20040255B3 (en) | 2006-02-28 |
Family
ID=26714105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20040255A HRPK20040255B3 (en) | 2001-08-16 | 2004-03-15 | Processes for preparing calcium salt forms of statins |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1425287A4 (fr) |
JP (2) | JP4188826B2 (fr) |
CN (1) | CN100430405C (fr) |
AU (1) | AU2002324715B2 (fr) |
CA (1) | CA2450820C (fr) |
CZ (1) | CZ2004337A3 (fr) |
HR (1) | HRPK20040255B3 (fr) |
HU (1) | HUP0500616A3 (fr) |
IL (2) | IL160077A0 (fr) |
IS (1) | IS7148A (fr) |
MX (1) | MXPA04001451A (fr) |
NO (1) | NO20041082L (fr) |
NZ (1) | NZ529913A (fr) |
PL (1) | PL370407A1 (fr) |
SK (1) | SK1402004A3 (fr) |
TR (1) | TR200302281T2 (fr) |
WO (1) | WO2003016317A1 (fr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
AU2002232891B2 (en) * | 2000-11-16 | 2006-12-14 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
WO2002057229A1 (fr) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE) |
US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
CA2412012C (fr) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Matrice extracellulaire resorbable contenant du collagene i et du collagene ii pour la reconstruction de cartilage |
WO2003078379A1 (fr) | 2002-03-18 | 2003-09-25 | Biocon Limited | Inhibiteurs de hmg-coa reductase amorphe avec taille souhaitee des particules |
AR039836A1 (es) * | 2002-05-21 | 2005-03-02 | Ranbaxy Lab Ltd | Proceso para la preparacion de un aldehido de pirimidina util para la preparacion de rosuvastatina |
US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
PL376557A1 (pl) * | 2003-02-12 | 2006-01-09 | Ciba Specialty Chemicals Holding Inc. | Postacie krystaliczne pitawastatyny wapnia |
EP1631533B1 (fr) | 2003-04-22 | 2009-03-11 | Biocon Limited | Nouveau procede pour une reduction stereoselective de beta-setoesters |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
WO2005012246A1 (fr) | 2003-07-25 | 2005-02-10 | Avecia Pharmaceuticals Limited | Procede et composes intermediaires servant a la preparation de statines, notamment d'atorvastatine |
AU2003269477A1 (en) * | 2003-08-26 | 2005-03-10 | Biocon Limited | Novel process for preparation of 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3, 5-dihydroxy-6-heptenoic acid sodium salt |
EP1816126A1 (fr) * | 2003-08-28 | 2007-08-08 | Teva Pharmaceutical Industries Limited | Procédé pour la préparation de rosuvastatine calcique |
CA2537271A1 (fr) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Procede de preparation de sels calciques de rosuvastatine |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
AU2003272080A1 (en) | 2003-09-18 | 2005-04-06 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
WO2005040134A1 (fr) * | 2003-10-22 | 2005-05-06 | Ranbaxy Laboratories Limited | Procede de preparation de rosuvastatine calcique amorphe |
GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
EP1601658A1 (fr) | 2003-11-24 | 2005-12-07 | Teva Pharmaceutical Industries Limited | Sels d'ammonium cristallins de la rosuvastatine |
MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
EP1689723B1 (fr) | 2003-12-02 | 2011-04-27 | Teva Pharmaceutical Industries, Ltd. | Norme de reference pour la caracterisation de la rosuvastatine |
TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
JP2007517028A (ja) * | 2003-12-29 | 2007-06-28 | レツク・フアーマシユーテイカルズ・デー・デー | 非晶質の(4r−シス)−6−[2−[3−フェニル−4−(フェニルカルバモイル)−2−(4−フルオロフェニル)−5−(1−メチルエチル)−ピロール−1−イル]−エチル]−2,2−ジメチル−[1,3]−ジオキサン−4−イル−酢酸を調製する方法 |
CZ200486A3 (cs) * | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny |
WO2005077917A1 (fr) * | 2004-01-19 | 2005-08-25 | Ranbaxy Laboratories Limited | Sels de magnesium amorphes de la rosuvastatine |
SI21745A (sl) * | 2004-04-09 | 2005-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
JP2007508379A (ja) | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Tempo媒介型酸化段階を包含するロスバスタチンの調製方法 |
US7642287B2 (en) | 2004-08-06 | 2010-01-05 | Transform Pharmaceuticals, Inc. | Statin pharmaceutical compositions and related methods of treatment |
CA2591439C (fr) | 2005-02-22 | 2013-03-26 | Teva Pharmaceutical Industries Ltd. | Rosuvastatine, sels de rosuvastatine exempts de son alkylether, procede d'elaboration correspondant |
CZ299215B6 (cs) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
CN101500555A (zh) * | 2005-08-04 | 2009-08-05 | 变换药品公司 | 包含非诺贝特和他汀的新型制剂及相关治疗方法 |
WO2007022488A2 (fr) | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Intermediaire de rosuvastatine sous forme cristalline |
CN100371709C (zh) * | 2005-12-12 | 2008-02-27 | 重庆医药工业研究院有限责任公司 | 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法 |
ES2564250T3 (es) | 2006-05-03 | 2016-03-21 | Msn Laboratories Private Limited | Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas |
HUE028475T2 (en) | 2006-10-09 | 2016-12-28 | Msn Laboratories Private Ltd | A novel process for the preparation of statins and their pharmaceutically acceptable salts |
EP2022784A1 (fr) | 2007-08-08 | 2009-02-11 | LEK Pharmaceuticals D.D. | Procédé pour la préparation d'ester méthylique de rosuvastatine |
WO2010089770A2 (fr) | 2009-01-19 | 2010-08-12 | Msn Laboratories Limited | Procédé amélioré d'élaboration d'acide (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophényl)quinolin-3-yl]-3,5-dihydroxy-6(e)-heptènoïque de haute pureté, y compris ses sels pharmaceutiquement acceptables |
WO2011086584A2 (fr) | 2010-01-18 | 2011-07-21 | Msn Laboratories Limited | Procédé amélioré pour la préparation d'intermédiaires amides et leur utilisation |
HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
EP3178812A1 (fr) * | 2010-11-12 | 2017-06-14 | Hetero Research Foundation | Nouveaux polymorphes de calcium de pitavastatine |
HU229260B1 (en) * | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
CN102875504A (zh) * | 2011-07-13 | 2013-01-16 | 华南理工大学 | 4,5,6,7-四氢普伐他汀及其盐在心血管上的用途 |
CN102302452B (zh) * | 2011-09-14 | 2012-11-21 | 海南美大制药有限公司 | 匹伐他汀钙脂质体固体制剂 |
CN102796036B (zh) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | 一种阿托伐他汀钙的制备方法 |
CN103724278B (zh) * | 2013-12-12 | 2019-03-29 | 江苏阿尔法药业有限公司 | 他汀类中间体及其衍生物的制备方法 |
EP3103878A4 (fr) * | 2014-02-06 | 2017-08-16 | API Corporation | Calcium de rosuvastatine et procédé de production d'un intermédiaire de celui-ci |
KR20160126700A (ko) | 2015-04-24 | 2016-11-02 | 미래파인켐 주식회사 | 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법 |
CN105111173B (zh) * | 2015-06-26 | 2017-06-23 | 上海应用技术学院 | 他汀含氟衍生物及其用途 |
CN105017231B (zh) * | 2015-06-26 | 2018-01-26 | 上海应用技术学院 | 多取代吲哚类他汀含氟修饰物及其用途 |
EP3333155B1 (fr) | 2015-08-05 | 2023-05-24 | API Corporation | Procédé de production du sel de calcium de pitavastatine |
CN111362856B (zh) * | 2020-04-29 | 2023-08-18 | 福建海西新药创制股份有限公司 | 一种利用微反应装置生产阿托伐他汀钙的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5817443B2 (ja) * | 1976-11-02 | 1983-04-07 | 三共株式会社 | Ml−236b金属塩を主成分とする高脂血症治療剤 |
US4137322A (en) * | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
US4857547A (en) * | 1988-01-07 | 1989-08-15 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
ES2167587T3 (es) * | 1995-07-17 | 2002-05-16 | Warner Lambert Co | Forma cristalina de la sal hemicalcica del acido (r-(r*,r*))-2-(4-fluorofenil)-beta,delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico (atorvastatina). |
US5669156A (en) * | 1996-08-28 | 1997-09-23 | Fleetwood Systems, Inc. | Can end curing system with magnetic fanning and belt conveying |
NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
WO2000053173A1 (fr) * | 1999-03-08 | 2000-09-14 | Merck & Co., Inc. | Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase |
AU2002232891B2 (en) * | 2000-11-16 | 2006-12-14 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
AU2007205725A1 (en) * | 2000-11-30 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
CA2431068C (fr) * | 2000-12-27 | 2008-06-10 | Ciba Specialty Chemicals Holding Inc. | Formes cristallines d'atorvastatine |
US7563911B2 (en) * | 2001-08-31 | 2009-07-21 | Morepen Laboratories Ltd. | Process for the preparation of amorphous atorvastin calcium salt (2:1) |
-
2002
- 2002-08-16 IL IL16007702A patent/IL160077A0/xx active IP Right Grant
- 2002-08-16 HU HU0500616A patent/HUP0500616A3/hu unknown
- 2002-08-16 NZ NZ529913A patent/NZ529913A/en unknown
- 2002-08-16 CA CA2450820A patent/CA2450820C/fr not_active Expired - Fee Related
- 2002-08-16 CZ CZ2004337A patent/CZ2004337A3/cs unknown
- 2002-08-16 PL PL02370407A patent/PL370407A1/xx unknown
- 2002-08-16 JP JP2003521239A patent/JP4188826B2/ja not_active Expired - Lifetime
- 2002-08-16 AU AU2002324715A patent/AU2002324715B2/en not_active Expired - Fee Related
- 2002-08-16 EP EP02759374A patent/EP1425287A4/fr not_active Withdrawn
- 2002-08-16 MX MXPA04001451A patent/MXPA04001451A/es not_active Application Discontinuation
- 2002-08-16 TR TR2003/02281T patent/TR200302281T2/xx unknown
- 2002-08-16 WO PCT/US2002/026012 patent/WO2003016317A1/fr active IP Right Grant
- 2002-08-16 SK SK140-2004A patent/SK1402004A3/sk not_active Application Discontinuation
- 2002-08-16 CN CNB028159993A patent/CN100430405C/zh not_active Expired - Fee Related
-
2004
- 2004-01-27 IL IL160077A patent/IL160077A/en not_active IP Right Cessation
- 2004-02-11 IS IS7148A patent/IS7148A/is unknown
- 2004-03-15 HR HR20040255A patent/HRPK20040255B3/xx not_active IP Right Cessation
- 2004-03-15 NO NO20041082A patent/NO20041082L/no not_active Application Discontinuation
-
2008
- 2008-07-15 JP JP2008184147A patent/JP2009024008A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CZ2004337A3 (cs) | 2005-01-12 |
CN100430405C (zh) | 2008-11-05 |
CN1543468A (zh) | 2004-11-03 |
CA2450820A1 (fr) | 2003-02-27 |
EP1425287A4 (fr) | 2005-09-07 |
JP4188826B2 (ja) | 2008-12-03 |
SK1402004A3 (sk) | 2005-01-03 |
AU2002324715B2 (en) | 2009-03-12 |
NO20041082L (no) | 2004-03-15 |
CA2450820C (fr) | 2011-03-15 |
IL160077A0 (en) | 2004-06-20 |
PL370407A1 (en) | 2005-05-30 |
IL160077A (en) | 2007-10-31 |
HUP0500616A3 (en) | 2011-07-28 |
EP1425287A1 (fr) | 2004-06-09 |
WO2003016317A1 (fr) | 2003-02-27 |
NZ529913A (en) | 2005-03-24 |
JP2009024008A (ja) | 2009-02-05 |
JP2005500382A (ja) | 2005-01-06 |
HUP0500616A2 (hu) | 2005-11-28 |
TR200302281T2 (tr) | 2004-09-21 |
IS7148A (is) | 2004-02-11 |
MXPA04001451A (es) | 2005-02-17 |
HRP20040255A2 (en) | 2004-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRPK20040255B3 (en) | Processes for preparing calcium salt forms of statins | |
RS51136B (sr) | Supstituisani pirolopiridini, kompozicije koje ih sadrže, postupak za njihovo dobijanje i upotreba | |
IN2012DN00758A (fr) | ||
MY140390A (en) | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | |
ID17851A (id) | Persenyawaan heterosiklis, produksi dan pemakaiannya | |
TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
TW200633991A (en) | Chemical compounds | |
MY153045A (en) | Oxopyrazine derivative and herbicide | |
MX281941B (en) | Anthranilamide compounds, process for their production and pesticides containing them | |
ATE222895T1 (de) | Zwischenprodukte zur hertellung von oxazolidindion- und thiazolidindionderivate | |
PL370990A1 (en) | Sulfonyl-derivatives as novel inhibitors of histone deacetylase | |
MXPA04008796A (es) | Derivados de carbonilamino como novedosos inhibidores de desacetilasa de histona. | |
HRP20050361B1 (hr) | Novi postupak za industrijsku sintezu tetraestera 5-[bis(karboksimetil)amino]-3-karboksimetil-4-cijano-2-tiofenkarboksilne kiseline i njihova primjena u sintezi bivalentnih soli ranelinske kiseline i njihovih hidrata | |
MY149180A (en) | Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof | |
MEP10308A (en) | Benzoylpyridine derivative or its salt, fungicide containing it as an active ingredient, its production process and intermediate for producing it | |
DK0979821T3 (da) | Tricykliske forbindelser | |
DE60332350D1 (de) | Disazofarbstoffe und sie enthaltende tintenstrahldrucktinten | |
MY122255A (en) | Acrylonitrile compounds, process for their production and pesticides containing them | |
SI1483245T1 (sl) | 5-substituirani alkilaminopirazolni derivati kot pesticidi | |
DE60228990D1 (de) | Bicyclische verbindung | |
BR0211903A (pt) | Isoxazolopiridinonas | |
EA200200611A1 (ru) | Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции | |
DE602005010369D1 (de) | 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren | |
HK1130496A1 (en) | 3'-ethynylcytidine derivative 3'- | |
EA200300458A1 (ru) | Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
AKOB | Publication of a request for the grant of a patent not including a substantive examination of a patent application (a consensual patent) | ||
PKB1 | Consensual patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20110808 Year of fee payment: 10 |
|
PK10 | Patent expired after termination of 10 years for consensual patent |
Effective date: 20120817 |